Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT02875366
A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT02823470
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 62
- Registration Number
- NCT02797132
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 14
- Registration Number
- NCT02742519
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 41
- Registration Number
- NCT02730208
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 57
- Registration Number
- NCT02725567
A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
Completed
- Conditions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 368
- Registration Number
- NCT02722057
Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT02669849
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 124
- Registration Number
- NCT02660424
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1131
- Registration Number
- NCT02565914
© Copyright 2024. All Rights Reserved by MedPath